Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Biosimilar insulins – here they come

October 18th 2014

On September 10th 2014, the European Commission granted marketing authorisation for an insulin glargine, indicated to treat diabetes in adults, adolescents and children from the age of 2 years. This was the first insulin to be approved through the European Medicines Agency’s biosimilar pathway and followed ‘tentative approval’ for the same product from the Food and Drug Administration. The ‘tentative’ approval is the result of a patent infringement lawsuit in the US and anticipated delays almost certainly mean that Europe (and possibly the UK) will see the first launch.

So, what is the difference between a biosimilar and the generic products that have become so familiar? Generics are copies of small molecules derived from chemical manufacturing processes, and so are essentially identical to the original drug. In contrast, biosimilars are more complex peptides which, although they have an identical amino acid sequence, are made by biotechnological processes (such as yeast or bacterial fermentation). This means that the final 3-dimentional structure can be quite different to the original and so an identical pharmacological response cannot be guaranteed.

To be deemed ‘biosimilar’, the regulatory authorities require: similar pharmacokinetic and dynamic characteristics to the original; similar clinical efficacy; and no clinically meaningful differences in immunogenicity or adverse event profile from the reference product. These are much less stringent than would be required for a new diabetes therapy and do not, for example, include prohibitively expensive cardiovascular outcome studies.

Biosimilar products are not new, with sixteen biosimilars already approved in Europe across five product classes. Indeed, biosimilar glargine insulins have been commercially available for almost ten years but in regulatory areas which might be seen as less stringent than the US and EU. What seems certain is that biosimilars are about to join an increasingly complex UK basal insulin market, with at least three new products set to be launched over the coming 12 months….

Professor Steve Bain

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaBoehringer IngelheimNovo NordiskNapp Diabetes

Silver Sponsors

About Ascensia Diabetes CareAbbott Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership